Cat. No.: HY-12012

SB 216763

47 Cited Publications

Customer Review

Based on 47 publication(s) in Google Scholar

SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

For research use only. We do not sell to patients.

Purity: 99.76%
CAS No.: 280744-09-4
Formula: C₁₉H₁₂Cl₂N₂O₂
Molecular Weight:371.22

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

SB 216763 Chemical Structure

CAS No.: 280744-09-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (47)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

IC₅₀ & Target^[5]

GSK-3α

34.3 nM (IC₅₀)

GSK-3β

34.3 nM (IC₅₀)

All GSK-3 Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Fibroblast	IC₅₀	3 μM Compound: 6, SB216763	Inhibition of human SOD1 expressed in mouse fibroblasts after 48 hrs by ELISA relative to control Inhibition of human SOD1 expressed in mouse fibroblasts after 48 hrs by ELISA relative to control	[PMID: 24560539]
HEK293	EC₅₀	0.2 μM Compound: SB-216763	Glycogen synthase activity of HEK293 cells, inhibition of GSK3-beta Glycogen synthase activity of HEK293 cells, inhibition of GSK3-beta	[PMID: 12941331]
HEK293	EC₅₀	0.2 μM Compound: SB-216763	Effective concentration of compound against glycogen synthase kinase-3 in HEK293 cells Effective concentration of compound against glycogen synthase kinase-3 in HEK293 cells	[PMID: 15149684]
HEK293	EC₅₀	3.6 μM Compound: 8	Activation of GSK-3 in HEK293 cells assessed as induction in beta-catenin-LEF/TCF regulated reporter gene transcription Activation of GSK-3 in HEK293 cells assessed as induction in beta-catenin-LEF/TCF regulated reporter gene transcription	[PMID: 30616053]
MIA PaCa-2	IC₅₀	25 μM Compound: 78, SB-216763	Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 19338355]

In Vitro

SB-216763 (10-20 μM) induces β-catenin mediated-transcription in a dose-dependent manner in HEK293 cells. SB-216763 (10, 15 and 20 μM) can maintain mESCs with a pluripotent-like morphology in long-term culture. SB-216763 (10 μM) can maintain J1 mESCs in a pluripotent state for more than a month^[2].
SB-216763 inhibits GSK-3 with IC₅₀ of 34 nM^[3].
SB-216763 is equally effective at inhibiting human GSK-3α and GSK-3β^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SB216763 (20 mg/kg, i.v.) significantly improves the survival of BLM-treated mice. Mice randomized to receive BLM plus SB216763 shows a noteworthy reduction, compared with BLM-treated mice. SB216763 (20 mg/kg, i.v.) reduces the magnitude of BLM-induced alveolitis^[1]. SB 216763 (0.2 mg/kg, i.v.) with either 17β-E₁₀₀ or Geni₁₀₀ significantly reduce infarct size when the rabbits' hearts are submitted to 30-min CAO^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 280744-09-4
Appearance Solid
Molecular Weight 371.22
Formula C₁₉H₁₂Cl₂N₂O₂
Color Orange to red
SMILES

O=C(NC1=O)C(C2=CC=C(C=C2Cl)Cl)=C1C3=CN(C4=C3C=CC=C4)C
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (47)

All WBIF

Sort by:

Journal Impact Factor

Cell Res

Derivation of totipotent-like stem cells with blastocyst-like structure forming potential. [Abstract]

2022 Jun;32(6):513-529. PMID: 35508506
Nat Commun

Insulin action and resistance are dependent on a GSK3β-FBXW7-ERRα transcriptional axis. [Abstract]

2022 Apr 19;13(1):2105. PMID: 35440636
Adv Sci (Weinh)

Hyperlipidemia Aggravates Alveolar Bone Loss via Periodontal Ligament Stem Cell Ferroptosis Through GSK3β Dependent Ubiquitin-Mediated NRF2 Degradation. [Abstract]

2026 Jun;13(36):e75157. PMID: 41945797
Theranostics

Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System. [Abstract]

2019 Aug 12;9(20):5769-5783. PMID: 31534518
Haematologica

Multilevel defects in the hematopoietic niche in essential thrombocythemia. [Abstract]

2020 Mar;105(3):661-673. PMID: 31289202
Brain Behav Immun

2026 Jun 22:137:106877. PMID: 42331299
Biomed Pharmacother

Pharmacological interventions on GSK3β phosphorylation-mediated tau aggregation by modulating phase separation of tau proline-rich domain. [Abstract]

2025 Jun 27:189:118290. PMID: 40580878
Biomed Pharmacother

Dexmedetomidine prevents septic myocardial dysfunction in rats via activation of α7nAChR and PI3K/Akt- mediated autophagy. [Abstract]

2019 Dec;120:109231. PMID: 31546082
Br J Cancer

Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. [Abstract]

2023 Mar;128(7):1344-1359. PMID: 36717670
Cell Mol Life Sci

Dual phosphorylation of glycogen synthase kinase 3β differentially integrates metabolic programs to determine T cell immunity across vertebrates. [Abstract]

2025 May 28;82(1):218. PMID: 40434714
Biochem Pharmacol

Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell. [Abstract]

2018 Apr:150:280-292. PMID: 29475060

SB 216763 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2018 Apr:150:280-292. [Abstract]

Expression of c-Myc in MKN-45 cells treated with Lanatoside C and SB216763 at indicated concentrations for 24 h.
Life Sci

SGK1 inhibits oxidative injury and extracellular matrix degradation by activating the GSK-3β (Ser9)/Fyn/NRF2 pathway in pelvic organ prolapse. [Abstract]

2025 Aug 30:380:123939. PMID: 40889699
Life Sci

Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. [Abstract]

2020 Sep 1;256:117983. PMID: 32565252
Int J Mol Sci

Inhibition of ERK1/2 or CRMP2 Disrupts Alcohol Memory Reconsolidation and Prevents Relapse in Rats. [Abstract]

2024 May 17;25(10):5478. PMID: 38791516
Biomolecules

The Osteocyte with SB216763-Activated Canonical Wnt Signaling Constructs a Multifunctional 4D Intelligent Osteogenic Module. [Abstract]

2024 Mar 15;14(3):354. PMID: 38540772
Front Bioeng Biotechnol

Sustained release of a highly specific GSK3β inhibitor SB216763 in the PCL scaffold creates an osteogenic niche for osteogenesis, anti-adipogenesis, and potential angiogenesis. [Abstract]

2023 Jul 28:11:1215233. PMID: 37576993
Front Pharmacol

Number 2 Feibi Recipe Inhibits H2O2-Mediated Oxidative Stress Damage of Alveolar Epithelial Cells by Regulating the Balance of Mitophagy/Apoptosis. [Abstract]

2022 Mar 17;13:830554. PMID: 35370684
Int Immunopharmacol

OPTN ameliorates chondrocyte apoptosis in temporomandibular joint osteoarthritis by modulating ER-mitochondria Ca2+ transfer. [Abstract]

2025 May 7:157:114796. PMID: 40339496
Biosci Rep

The Wnt/β-catenin pathway regulates inflammation and apoptosis in ventilator-induced lung injury. [Abstract]

2023 Mar 31;43(3):BSR20222429. PMID: 36825682
Eur J Pharmacol

GSK-3β-mediated activation of NLRP3 inflammasome leads to pyroptosis and apoptosis of rat cardiomyocytes and fibroblasts. [Abstract]

2022 Apr 5;920:174830. PMID: 35182545
J Mol Cell Cardiol

Glycogen synthase kinase-3β inhibition alleviates activation of the NLRP3 inflammasome in myocardial infarction. [Abstract]

2020 Dec;149:82-94. PMID: 32991876
Cancers (Basel)

Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma. [Abstract]

2022 Nov 28;14(23):5854. PMID: 36497337
Drug Dev Res

Apigenin alleviates doxorubicin-induced myocardial pyroptosis by inhibiting glycogen synthase kinase-3β in vitro and in vivo. [Abstract]

2024 Jun;85(4):e22196. PMID: 38812449
Mol Nutr Food Res

Gallic Acid Attenuates Sepsis-Induced Liver Injury through C/EBPβ-Dependent MAPK Signaling Pathway. [Abstract]

2024 May 29:e2400123. PMID: 38809052
iScience

GSK3β/HIF-1α signaling-dependent anti-parasite effect of Cynanchi atrati Radix. [Abstract]

2025 Dec 1;29(1):114292. PMID: 41509906
J Funct Foods

2025 Apr.
Sci Rep

hUMSCs restore ovarian function in POI mice by regulating GSK3β-mediated mitochondrial dynamic imbalances in theca cells. [Abstract]

2024 Aug 16;14(1):19008. PMID: 39152165
J Biol Chem

Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma. [Abstract]

2024 Apr;300(4):107208. PMID: 38521502
Sci Rep

Empagliflozin protects against renal ischemia/reperfusion injury in mice. [Abstract]

2022 Nov 11;12(1):19323. PMID: 36369319
Cell Signal

PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy. [Abstract]

2025 Dec 19:139:112333. PMID: 41423011
Biochim Biophys Acta Mol Cell Res

Hepatocyte growth factor attenuates high glucose-disturbed mitochondrial dynamics in podocytes by decreasing ARF6-dependent DRP1 translocation. [Abstract]

2023 Oct 31;1871(1):119623. PMID: 37913847
Toxicol Appl Pharmacol

Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt/β-catenin signaling. [Abstract]

2020 Jan 1;386:114813. PMID: 31715269
Toxicol Appl Pharmacol

Inhibition of glycogen synthase kinase 3beta ameliorates triptolide-induced acute cardiac injury by desensitizing mitochondrial permeability transition. [Abstract]

2016 Dec 15:313:195-203. PMID: 27751939

SB 216763 purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2016 Dec 15:313:195-203. [Abstract]

SB 216763 blocks augmentation of phosphor-glycogen synthase and depletion of inhibitory phosphorylated GSK-3β at serine 9 sites, but maintains total GSK-3β levels. Cardiac protection following SB 216763 is dependent on GSK-3β activity inhibition, not on decrease in basal GSK-3β levels. H9c2 cells are treated with 160 nM TP for 24 h after pretreatments with 2 μM SB 216763 or vehicle 2 h later. Levels of p-GS, p-GSK-3β, GSK-3β and GAPDH are measured by western blot.
Mol Carcinog

BTG1 Acts as a Critical Tumor Suppressor Link Between HDAC Inhibition and β-Catenin Signaling Suppression in Diffuse Large B-Cell Lymphoma. [Abstract]

2026 Jun;65(6):754-769. PMID: 41950351
Int J Med Sci

RIP1-dependent Apoptosis and Differentiation Regulated by Skp2 and Akt/GSK3β in Acute Myeloid Leukemia. [Abstract]

2022 Mar 6;19(3):525-536. PMID: 35370472
Naunyn Schmiedebergs Arch Pharmacol

5-Methoxyflavone inhibits the proliferation of lung adenocarcinoma cells through PI3K/AKT/GSK3β/β-catenin/Cyclin D1 signaling and attenuates chemoresistance and PD-L1 expression. [Abstract]

2025 Oct 31. PMID: 41168435
Mol Immunol

Luteolin attenuates type 2 inflammation in asthmatic mice induced by OVA by regulating IL-33/ST2- GSK3β-M2 macrophage polarization. [Abstract]

2025 Oct:186:1-12. PMID: 40752323
J Cell Biochem

SB-216763, a GSK-3β inhibitor, protects against aldosterone-induced cardiac, and renal injury by activating autophagy. [Abstract]

2018 Jul;119(7):5934-5943. PMID: 29600538

SB 216763 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Jul;119(7):5934-5943. [Abstract]

SB-216763 activates cardiac autophagy. Cardiac protein expression of LC3-I, LC3-II, and p62 are assayed in cardiac tissues treated with Aldo-salt or with Aldo-salt plus SB-216763.

SB 216763 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Jul;119(7):5934-5943. [Abstract]

SB-216763 activates cardiac autophagy. Images showing immunofluorescent staining for LC3-II for among different groups as indicated.

SB 216763 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Jul;119(7):5934-5943. [Abstract]

SB-216763 activates renal autophagy. Renal protein expression of LC3-I, LC3-II and p62 are assayed in renal tissues treated with Aldo-salt or with Aldo-salt plus SB-216763. SB-216763 increased the Aldo-salt-induced autophagy.

SB 216763 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Jul;119(7):5934-5943. [Abstract]

SB-216763 activates renal autophagy. Representative micrographs showing immunofluorescent staining for LC3-II for among different groups as indicated.
SLAS Discov

Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ. [Abstract]

2024 Nov 5;29(8):100191. PMID: 39510350
Theriogenology

SB216763 enhances proliferation and sustains the undifferentiated state of porcine spermatogonial cells in prolonged In vitro culture. [Abstract]

2026 Apr 1:254:117816. PMID: 41518868
Biochem Biophys Res Commun

Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells. [Abstract]

2020 May 14;525(4):1074-1080. PMID: 32184020
Radiat Med Prot

2026 Jun 12.
bioRxiv

2023 Dec 13.
SSRN

2023 Jun 20.
University of Rijeka

2023.
Evid Based Complement Alternat Med

Calycosin Ameliorates Bleomycin-Induced Pulmonary Fibrosis via Suppressing Oxidative Stress, Apoptosis, and Enhancing Autophagy. [Abstract]

2022 Oct 11:2022:9969729. PMID: 36267093
Evid Based Complement Alternat Med

Antimetastasis Effect of Astragalus membranaceus- Curcuma zedoaria via β-Catenin Mediated CXCR4 and EMT Signaling Pathway in HCT116. [Abstract]

2019 May 30:2019:9692350. PMID: 31275425

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (269.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6938 mL

13.4691 mL

26.9382 mL

5 mM

0.5388 mL

2.6938 mL

5.3876 mL

10 mM

0.2694 mL

1.3469 mL

2.6938 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.73 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

MESCs maintained with LIF or 10 µM SB-216763 for more than a month are resuspended at 40,000 cells/mL in LIF-free mESC medium. EBs are prepared by a hanging drop procedure. Briefly, 20 µL drops containing mESCs are pipetted on the inside of a 10-cm Petri dish lid. The lids are placed onto Petri dishes containing 10 mL of HBSS and the EBs are allowed to form and grow for 4 days in the incubator. After 4 days, 15-20 EBs are transferred to a well containing LIF-free mESC medium in a 24-well plate. The medium is exchanged every two days and autonomously beating cell aggregates are observed and counted.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice are allocated to four groups (n=12/group) as follows: 1) intratracheal saline + vehicle (25% dimethyl sulfoxide, 25% polyethylene glycol, and 50% saline), 2) intratracheal saline + SB216763 (20 mg/kg) dissolved in vehicle, 3) intratracheal BLM (3 U/kg) + vehicle, and 4) intratracheal BLM + SB216763 (20 mg/kg) in vehicle. Another set of experiments to assess cytokine expression by reverse transcription-PCR is conducted in the mice (n=12/group) to receive 1) intratracheal saline + vehicle, 2) intratracheal BLM, and 3) intratracheal BLM + SB216763. To induce pulmonary fibrosis, BLM is intratracheally administered in mice (n=15/group) on day 0. BLM and saline-treated mice are administered with SB216763 dissolved in vehicle or vehicle alone intravenously at day 0 and then intraperitoneally twice a week until day 28. Mice are sacrificed by CO₂ inhalation on days 2, 7, and 28. In the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) experiments, the cohorts of mice are as follows: saline-treated (n=6), BLM-treated (n=6), and BLM + SB216763-treated (n=6).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Gurrieri, et al. 3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), a glycogen synthase kinase-3 inhibitor, displays therapeutic properties in a mouse model of pulmonary inflammation and fibrosis. J.Pharmacol.Exp.Ther.2010 [Content Brief]

[2]. Kirby LA, et al. Glycogen synthase kinase 3 (GSK3) inhibitor, SB-216763, promotes pluripotency in mouse embryonic stem cells.PLoS One. 2012;7(6):e39329. Epub 2012 Jun 26. [Content Brief]

[3]. Wang M, et al. The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3).Bioorg Med Chem Lett. 2011 Jan 1;21(1):245-9. Epub 2010 Nov 11. [Content Brief]

[4]. The ceiling effect of pharmacological postconditioning with the phytoestrogen genistein is reversed by the GSK3beta inhibitor SB 216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione] through mitochondrial ATP-dependent potassium channel opening. [Content Brief]

[5]. Coghlan MP, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000 Oct;7(10):793-803. [Content Brief]

[6]. Wang W, et al. Inhibition of glycogen synthase kinase 3beta ameliorates triptolide-induced acute cardiac injury by desensitizing mitochondrial permeability transition. Toxicol Appl Pharmacol. 2016 Dec 15;313:195-203. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6938 mL	13.4691 mL	26.9382 mL	67.3455 mL
	5 mM	0.5388 mL	2.6938 mL	5.3876 mL	13.4691 mL
	10 mM	0.2694 mL	1.3469 mL	2.6938 mL	6.7346 mL
	15 mM	0.1796 mL	0.8979 mL	1.7959 mL	4.4897 mL
	20 mM	0.1347 mL	0.6735 mL	1.3469 mL	3.3673 mL
	25 mM	0.1078 mL	0.5388 mL	1.0775 mL	2.6938 mL
	30 mM	0.0898 mL	0.4490 mL	0.8979 mL	2.2449 mL
	40 mM	0.0673 mL	0.3367 mL	0.6735 mL	1.6836 mL
	50 mM	0.0539 mL	0.2694 mL	0.5388 mL	1.3469 mL
	60 mM	0.0449 mL	0.2245 mL	0.4490 mL	1.1224 mL
	80 mM	0.0337 mL	0.1684 mL	0.3367 mL	0.8418 mL
	100 mM	0.0269 mL	0.1347 mL	0.2694 mL	0.6735 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

SB 216763

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) SB 216763

All GSK-3 Isoforms

Biological Activity

Chemical Information

Publications (47)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

SB 216763 Related Classifications

HY-12012 Related Classifications